Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.
U.S. Supreme Court justices appeared sympathetic to Merck & Co. in the company’s bid to fend off hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with the osteoporosis drug Fosamax.
A federal judge in Maryland said The Johns Hopkins University, Bristol-Myers Squibb Co. and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis.
The Delaware Supreme Court said in a court filing that Germany’s Fresenius SE properly terminated the company’s merger agreement with Akorn Inc., sending shares of the U.S generic drugmaker down more than 30 percent.
Democrats reoriented their uphill push to block U.S. Senate confirmation of President Donald Trump’s nominee to the Supreme Court, moving healthcare to the center of their strategy and putting less emphasis on abortion rights.
A Missouri appeals court threw out a $55 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using talc-based products, including J&J’s baby powder, citing a U.S. Supreme court ruling on where such cases can be brought.
The U.S. Supreme Court agreed to hear Merck & Co.’s appeal of a lower court’s ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.
The U.S. Supreme Court delivered a blow to the nation’s pharmaceutical industry when it upheld the constitutionality of Inter Partes Review (IPR).
Massachusetts’ top court opened the door for consumers to sue Merck and other brand-name drug makers over injuries blamed on generic forms of their treatments made by other companies.